212 related articles for article (PubMed ID: 26375366)
1. Dual mTORC1/C2 inhibitors: gerosuppressors with potential anti-aging effect.
Sousa-Victor P; García-Prat L; Muñoz-Cánoves P
Oncotarget; 2015 Sep; 6(27):23052-4. PubMed ID: 26375366
[TBL] [Abstract][Full Text] [Related]
2. Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).
Leontieva OV; Demidenko ZN; Blagosklonny MV
Oncotarget; 2015 Sep; 6(27):23238-48. PubMed ID: 26177051
[TBL] [Abstract][Full Text] [Related]
3. Gerosuppression by pan-mTOR inhibitors.
Leontieva OV; Blagosklonny MV
Aging (Albany NY); 2016 Dec; 8(12):3535-3551. PubMed ID: 28077803
[TBL] [Abstract][Full Text] [Related]
4. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis.
Wang X; Lai P; Zhang Z; Huang M; Wang L; Yin M; Jin D; Zhou R; Bai X
Oncol Rep; 2014 Jul; 32(1):382-8. PubMed ID: 24840134
[TBL] [Abstract][Full Text] [Related]
5. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.
Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046
[TBL] [Abstract][Full Text] [Related]
6. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin, proliferation and geroconversion to senescence.
Blagosklonny MV
Cell Cycle; 2018; 17(24):2655-2665. PubMed ID: 30541374
[TBL] [Abstract][Full Text] [Related]
8. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
9. The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.
Zhang X; Wang X; Qin L; Xu T; Zhu Z; Zhong S; Zhang M; Shen Z
Urology; 2015 Jan; 85(1):273.e1-7. PubMed ID: 25440763
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island.
Arriola Apelo SI; Lamming DW
J Gerontol A Biol Sci Med Sci; 2016 Jul; 71(7):841-9. PubMed ID: 27208895
[TBL] [Abstract][Full Text] [Related]
11. Effect of mTORC1/mTORC2 inhibition on T cell function: potential role in graft-versus-host disease control.
Herrero-Sánchez MC; Rodríguez-Serrano C; Almeida J; San-Segundo L; Inogés S; Santos-Briz Á; García-Briñón J; SanMiguel JF; Del Cañizo C; Blanco B
Br J Haematol; 2016 Jun; 173(5):754-68. PubMed ID: 26914848
[TBL] [Abstract][Full Text] [Related]
12. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
Li H; Lin J; Wang X; Yao G; Wang L; Zheng H; Yang C; Jia C; Liu A; Bai X
Breast Cancer Res Treat; 2012 Aug; 134(3):1057-66. PubMed ID: 22476852
[TBL] [Abstract][Full Text] [Related]
13. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells.
Sini P; James D; Chresta C; Guichard S
Autophagy; 2010 May; 6(4):553-4. PubMed ID: 20364113
[TBL] [Abstract][Full Text] [Related]
15. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
16. From rapalogs to anti-aging formula.
Blagosklonny MV
Oncotarget; 2017 May; 8(22):35492-35507. PubMed ID: 28548953
[TBL] [Abstract][Full Text] [Related]
17. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.
Yu K; Toral-Barza L; Shi C; Zhang WG; Lucas J; Shor B; Kim J; Verheijen J; Curran K; Malwitz DJ; Cole DC; Ellingboe J; Ayral-Kaloustian S; Mansour TS; Gibbons JJ; Abraham RT; Nowak P; Zask A
Cancer Res; 2009 Aug; 69(15):6232-40. PubMed ID: 19584280
[TBL] [Abstract][Full Text] [Related]
18. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.
Pike KG; Malagu K; Hummersone MG; Menear KA; Duggan HM; Gomez S; Martin NM; Ruston L; Pass SL; Pass M
Bioorg Med Chem Lett; 2013 Mar; 23(5):1212-6. PubMed ID: 23375793
[TBL] [Abstract][Full Text] [Related]
19. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition.
Limon JJ; So L; Jellbauer S; Chiu H; Corado J; Sykes SM; Raffatellu M; Fruman DA
Proc Natl Acad Sci U S A; 2014 Nov; 111(47):E5076-85. PubMed ID: 25385646
[TBL] [Abstract][Full Text] [Related]
20. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.
Qian J; Chen Y; Meng T; Ma L; Meng L; Wang X; Yu T; Zask A; Shen J; Yu K
Oncotarget; 2016 Oct; 7(41):67071-67086. PubMed ID: 27563814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
